Zim Laboratories Limited (ZIMLAB) - Cash Flow Conversion Efficiency

Latest as of September 2023: 0.036x

Based on the latest financial reports, Zim Laboratories Limited (ZIMLAB) has a cash flow conversion efficiency ratio of 0.036x as of September 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs81.71 Million ≈ $883.66K USD) by net assets (Rs2.26 Billion ≈ $24.44 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Zim Laboratories Limited - Cash Flow Conversion Efficiency Trend (2013–2025)

This chart illustrates how Zim Laboratories Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Zim Laboratories Limited balance sheet liabilities for a breakdown of total debt and financial obligations.

Zim Laboratories Limited Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Zim Laboratories Limited ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Magnitude International Ltd Ordinary Shares
NASDAQ:MAGH
N/A
Molinos Juan Semino SA
BA:SEMI
0.001x
Tolins Tyres Ltd
NSE:TOLINS
N/A
Xplus SA
WAR:XPL
0.059x
Sequana Medical NV
BR:SEQUA
0.254x
Yuasa Battery (Thailand) Public Company Limited
BK:YUASA
0.099x
Davolink Inc.
KQ:340360
0.488x
2S Metal Public Company Limited
BK:2S
0.007x

Annual Cash Flow Conversion Efficiency for Zim Laboratories Limited (2013–2025)

The table below shows the annual cash flow conversion efficiency of Zim Laboratories Limited from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Zim Laboratories Limited.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-03-31 Rs2.52 Billion
≈ $27.28 Million
Rs411.55 Million
≈ $4.45 Million
0.163x +139.30%
2024-03-31 Rs2.39 Billion
≈ $25.82 Million
Rs162.78 Million
≈ $1.76 Million
0.068x -63.59%
2023-03-31 Rs2.00 Billion
≈ $21.67 Million
Rs375.19 Million
≈ $4.06 Million
0.187x -33.13%
2022-03-31 Rs1.76 Billion
≈ $19.00 Million
Rs492.06 Million
≈ $5.32 Million
0.280x +41.33%
2021-03-31 Rs1.61 Billion
≈ $17.38 Million
Rs318.51 Million
≈ $3.44 Million
0.198x +39.07%
2020-03-31 Rs1.54 Billion
≈ $16.64 Million
Rs219.15 Million
≈ $2.37 Million
0.142x -38.25%
2019-03-31 Rs1.51 Billion
≈ $16.34 Million
Rs348.65 Million
≈ $3.77 Million
0.231x -13.92%
2018-03-31 Rs1.37 Billion
≈ $14.77 Million
Rs366.13 Million
≈ $3.96 Million
0.268x -1.11%
2017-03-31 Rs1.18 Billion
≈ $12.80 Million
Rs320.71 Million
≈ $3.47 Million
0.271x +21.46%
2016-03-31 Rs983.37 Million
≈ $10.63 Million
Rs219.43 Million
≈ $2.37 Million
0.223x +276.37%
2015-03-31 Rs942.10 Million
≈ $10.19 Million
Rs55.85 Million
≈ $604.04K
0.059x +105.44%
2014-03-31 Rs1.16 Billion
≈ $12.55 Million
Rs33.48 Million
≈ $362.11K
0.029x +113.30%
2013-03-31 Rs1.07 Billion
≈ $11.55 Million
Rs-231.81 Million
≈ $-2.51 Million
-0.217x --

About Zim Laboratories Limited

NSE:ZIMLAB India Drug Manufacturers - Specialty & Generic
Market Cap
$46.35 Million
Rs4.29 Billion INR
Market Cap Rank
#22167 Global
#1225 in India
Share Price
Rs87.94
Change (1 day)
+3.05%
52-Week Range
Rs60.26 - Rs120.82
All Time High
Rs149.00
About

ZIM Laboratories Limited engages in the development, manufacture, and supply of generic pharmaceutical and nutraceutical products in India and internationally. It provides its products in pre- formulation intermediates and finished formulations in the oral solid dosage forms, such as pellets, taste-masked powders, granules, tablets, capsules, dry syrup, and oral thin films. The company offers the… Read more